IBL1002: Phase I study of indibulin in advanced solid tumors
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Indibulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 18 Jul 2012 Planned end date changed from 1 Dec 2008 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2009 Additional lead investigator (Lewis J) added as reported by ClinicalTrials.gov.